A Randomized Study on Postrelapse Disease-Free Survival with Adjuvant Mistletoe versus Oral Etoposide in Osteosarcoma Patients

Table 5

Frequency and intensity of adverse events (AE) and adverse drug reactions (ADR).

AE characteristics	Viscum   𝑁 [%]	Etoposide  𝑁 [%]	Total  𝑁 [%]
All AEs	16 [18.8]	69 [81.2]	85 [100.0]
Unfavorable AEs by
Severity
Severe	5 [5.88]	26 [30.59]	28 [36.47]
Outcome
AE unchanged	4 [4.76]	4 [4.76]	8 [9.52]
AE exacerbated	—	2 [2.38]	2 [2.38]
Study medication
Dose reduced	—	5 [5.88]	5 [5.88]
Use continued after interruption	1 [1.18]	18 [21.18]	19 [22.35]
Use discontinued	2 [2.35]	14 [16.47]	16 [18.82]
Adverse drug reactions (ADR)	2 [2.36]	47 [55.29]	49 [57.65]
Most frequent ADR
Neutropenia	—	12 [25.53]	12 [24.49]
Anaemia	—	6 [12.77]	6 [12.24]
Leukopenia	—	6 [12.77]	6 [12.24]
Nausea	—	5 [10.64]	5 [10.20]
Alopecia	—	4 [8.51]	4 [8.16]